The Latest Cardiac and Vascular News
SPARKS, Md., Aug. 12, 2022 (GLOBE NEWSWIRE) — TridentCare, a national leader of portable diagnostic services, announced the appointment of Daniel C. “Dan” Buning as Chief Executive Officer and member of the Board of Directors. Buning has had a distinguished career both in the military and private industry where he […]
VANCOUVER and MINNEAPOLIS, Aug. 11, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the second quarter ended June 30, 2022. Recent Highlights Generated revenues of $818,000, a quarterly record and a year-over-year increase of 29% over the second quarter […]
Company Remains on Track for FDA Submissions of the HeartBeam AIMI™ Software Platform for the Emergency Department in Q3 2022 & AIMIGo™, the Telehealth Solution, in Q4 2022 Acquires Source Code Access Under the LivMor Partnership Agreement that will be Used to Build a Company-branded Version of the LIVMOR’s Halo+ […]
MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the second quarter ended June 30, 2022, and provided an update on corporate activities. “The second quarter of 2022 marked […]
LONDON–(BUSINESS WIRE)–Silence Therapeutics plc (Nasdaq: SLN) (“Silence”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced the pricing of an underwritten offering of 5,950,000 American Depositary Shares (“ADSs”), each representing three […]
Corporate restructuring underway and MASTERS-2 clinical trial prioritized Conference call begins at 4:30 p.m. Eastern time today CLEVELAND–(BUSINESS WIRE)–Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three and six months ended June 30, 2022 and provided a business update. Second quarter 2022 Corporate and Operational Highlights: Corporate […]
— Phase 3 RAPID study reached the target of 180 confirmed PSVT events treated with double-blind study medication required to initiate primary efficacy analysis; topline data readout for RAPID study remains on track for mid-second half 2022 — Phase 3 PSVT study initiated in China MONTREAL and CHARLOTTE, N.C., Aug. 10, 2022 /PRNewswire/ — Milestone Pharmaceuticals […]
New CEO Appointed, Manufacturing Progress Noted TORONTO, Aug. 11, 2022 (GLOBE NEWSWIRE) — Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced financial results for the three and six months […]
Received State Licensing to Enable cGMP Manufacturing of Drug Product TN-201 and TN-301 IND Submissions on Track for Second Half 2022 Presented Preclinical Data for Multiple Pipeline Programs and Capsid Engineering Efforts SOUTH SAN FRANCISCO, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company […]
SUNNYVALE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the second quarter of 2022 and filed its quarterly report on Form 10-Q for the three and six months ended […]
